Anlotinib Recruiting Phase 2 Trials for Non-driver Mutation Advanced Non-Squamous Non Small Cell Lung Cancer / Non-Squamous Non Small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03646968Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous Non-small Cell Lung Cancer